← Back to All Filings

Lilly Endowment Sells $62.3M in Eli Lilly (LLY) Stock

Low SignificanceNovember 19, 2025 at 4:02:21 PM EST

ELI LILLY & Co

$LLY4CIK: 0000059478

Subscribe to track LLY

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Lilly Endowment Sells $62.3M in Eli Lilly (LLY) Stock

Company: ELI LILLY & Co (LLY) Form: 4 | Filed: 2025-11-19 Significance: Low

Insider: LILLY ENDOWMENT INC Relationship: Ten Percent Owner

Transaction: • Type: Sell • Shares: 60,213 • Avg. Price: $1,034.82 • Value: $62,309,615 • Owned After: 92,811,978

Key Insight: Despite the large dollar value, this sale represents a minuscule fraction (<0.1%) of the Endowment's total holdings and is immaterial relative to Eli Lilly's mega-cap status.

Market Context: Such sales by large foundations are often for liquidity or diversification and are not typically indicative of a change in outlook on the company.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: ELI LILLY & Co (LLY)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: Lilly Endowment Inc., a 10% owner, sold $62.3 million of Eli Lilly stock, a transaction that is insignificant relative to both its total holdings and the company's massive market capitalization.
  • Market Impact: The sale is too small to have a material impact on the stock and is likely part of a routine diversification or liquidity strategy for the foundation.

Company Information

FieldValue
CompanyELI LILLY & Co
Ticker SymbolLLY
CIK0000059478
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameLILLY ENDOWMENT INC
CIK0000316011
Title/Positionnull
RelationshipTen Percent Owner

Transaction Details

FieldValue
Form Type4
Transaction Date2025-11-18
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved60,213
Price Per Share$1,034.82 (Weighted Average)
Total Value$62,309,615
Shares Owned After92,811,978
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$62,309,615
% of Market Cap0.0068%
Shares Transacted60,213
% of Shares Outstanding0.0064%
Post-Transaction Ownership92,811,978 shares (9.81% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a mega-cap company with a market capitalization of $917.64 billion, a $62.3 million transaction is negligible and constitutes routine market activity.
  • Ownership Concentration: The sale represents a tiny fraction (approximately 0.065%) of the Endowment's total stake in Eli Lilly. The insider continues to hold a substantial position of over 9.8% of all outstanding shares.
  • Transaction Significance: The transaction's value and share count fall far below the thresholds for moderate or high significance (<0.1% of market cap and <0.1% of shares outstanding).

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale is immaterial in the context of the company's size and the insider's remaining position. It is unlikely to influence market sentiment or stock price.

Volume & Sentiment

  • Expected Volume Impact: Minimal. The number of shares sold is a small fraction of the stock's typical daily trading volume.
  • Sentiment Indicator: Neutral. This transaction is characteristic of a large foundation managing its portfolio for liquidity or diversification, not a bearish signal on the company's prospects.

Additional Context

Transaction Notes

  • Special Circumstances: The filing reports ten separate transactions on the same day, which have been aggregated for this analysis. The sales were executed at weighted average prices, a common practice for large block trades to minimize market impact.
Topics:#SECFiling#InsiderTrading#LLY#EliLilly#Form4#InsiderSell#StockMarket#Pharma#LillyEndowment

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.